The Rocco Laboratory, part of the OSUCCC – James and the Department of Otolaryngology-Head and Neck Surgery at Ohio State, studies the development and consequences of intra-tumor heterogeneity, the differences among cancer cells within a tumor. Intra-tumor heterogeneity lies at the core of cancer treatment resistance. Even if only a single cancer cell develops the ability to escape from the primary tumor site or becomes resistant to radiation, to standard or targeted chemotherapy, or to immunotherapy, that cell might regrow a tumor after therapy removes all the other cancer cells. The Rocco lab explores all aspects of intra-tumor heterogeneity, in an attempt to develop new approaches that can turn it from a barrier to therapeutic success into a target for therapy.
Dr. Rocco began his translational research laboratory in 1999 at the Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital (MGH). His early basic-science work on the regulation of tumor cell death following chemotherapy led him to translational work that identified the protein Bcl2 as a marker of poor response to standard therapy for oropharyngeal cancer. His NIH-supported laboratory then developed the first simple and general way to measure intra-tumor heterogeneity, and used it to show that high heterogeneity was associated with poor outcome in head and neck cancer. He moved his laboratory to Ohio State in 2015.
The faculty, students, and staff of the Rocco laboratory have a wide range of expertise ranging from cellular and molecular biology to translational and clinical research. Although the laboratory focuses on head and neck cancer, Dr. Rocco’s clinical specialty, its work has already helped to advance research on other types of cancer. The laboratory thus provides a balanced mix of basic and translational science projects that offers many unique research opportunities. Current work in the laboratory includes:
- Understanding how the functions of tumor suppressor proteins, especially p16, p14 and p53, can be lost, leading to development of heterogeneous tumors;
- Documenting the differences among cancer cells that allow only some of them, called cancer stem cells (CSC) or tumor initiating cells (TIC), to re-grow a tumor after therapy;
- Learning how genetic differences develop and are maintained among cancer cells in a tumor, providing a reservoir of cancer cells that might be resistant to particular therapies;
- Finding the best ways to measure these functional and genetic differences among cancer cells in a tumor;
- Studying how these types of differences influence patients’ responses to therapy for head and neck cancer; and
- Developing better ways to collect and process cancer cells from patients' tumors to support these studies.
Graduate students, postdoctoral researchers and medical students interested in the Rocco Lab should contact Gaila Konneker, administrative manager for head and neck cancer research, at email@example.com.
Present Lab Members:
Professor James W. Rocco, MD, PhD, holds the Mary E. and John W. Alford Research Chair in Head and Neck Cancer. In addition to directing his research laboratory, he has fruitful collaborations with the Getz group at the Broad Institute and the Bernstein lab at MGH that aim to understand the biological basis of intra-tumor heterogeneity. His laboratory research interests synergize with his interests in clinical trials, his roles as a head and neck surgeon and as Head and Neck Disease Group Leader at The James Cancer Hospital and Solove Research Institute, and his work with many groups devoted to improving clinical care of head and neck cancer patients.
Research Associate Professor Edmund Mroz, PhD, worked with Dr. Rocco to develop a measure of genetic differences among cancer cells in a tumor and to show its relation to outcome in head and neck cancer. Researchers studying other types of cancer are now adopting this approach. Since moving to Ohio State, Dr. Mroz had been extending this work to evaluate the relation of intra-tumor heterogeneity to head and neck cancer outcomes following specific types of therapy, with a long-term goal of helping to personalize therapy choices. He is working with colleagues at the Broad Institute to understand the early processes of tumor evolution that lead to intra-tumor heterogeneity, and provides senior-level supervision for Rocco laboratory students and staff.
Research Associate 2 Bin Li, PhD, is studying how loss of tumor suppressor functions leads to tumor development and heterogeneity. To model the initiating stages of squamous cell carcinoma (SCC), he uses CRISPR/Cas9-mediated genome editing to induce concurrent mutations in the TP53 and CDKN2A genes of primary keratinocytes. These include knockouts and mutations of the p53 protein (which promote heterogeneity) and individual or combined knockouts of the p14 and p16 protein products of the CDKN2A gene. This panel of genetically modified keratinocytes lines will help to dissect out the roles of CDKN2A and TP53 alterations in initiation and development of SCC and to identify actionable targets for developing novel treatments.
Research Associate 2 Jharna Datta, PhD, is deciphering how expression of the p16 tumor suppressor product of the CDKN2A gene is regulated. Her primary focus is how loss of the C-terminal binding protein (CtBP) could release the Polycomb–based repression of CDKN2A so that p16 protein is expressed constitutively, thus inhibiting cell proliferation. Targeting CtBP to activate p16-based tumor suppression could then lead to a novel therapeutic strategy to prevent head and neck squamous carcinogenesis.
Research Associate 1 Satavisha Roy, BS, is investigating the properties of cancer stem cells (CSC) in cell lines derived from Head and Neck Squamous Cell Carcinoma (HNSCC). She uses the ability of single cells to form tumorspheres, floating sphere-shaped structures, as a model to understand how CSC differ from other cancer cells and to find ways to target the CSC population.
Research Associate 1 Devi M Nair, PhD, is helping to develop the Head and Neck Tumor Heterogeneity project that will establish the best ways to use living cells from patients’ tumors for studies of heterogeneity. Devi processes tumors for live tissue/cell harvest to analyze complex cancer models such as tumorsphere formation from single cells, responses to drug treatments, and associations of cellular behaviors with patient clinical characteristics.
Research Associate 1 Caitlin Goodman, MS, who recently completed a Master’s of Science degree, brings a background in the study of genetics, replication stress and disease to the Rocco lab. She is expanding the use of adenoviral delivery of CRISPR technology for genetic editing in cells, in particular to elucidate the cellular pathways associated with the p16 and p14 products of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and the tumor suppressor p53. She also is responsible for day-to-day lab functions, ordering supplies, and organizing the lab.
Research Assistant 2 Jason Andersen, BS, provides skilled technical support for molecular biology studies in the laboratory. He is developing a system to use adenovirus to deliver CRISPR technology for editing genes in cells. The goal is to combine the ease of use and specificity of CRISPR with the advantages of adenoviruses, which unlike retroviruses do not directly alter the genome themselves. Jason particularly wants to use these tools to help elucidate cellular pathways associated with the p16 and p14 products of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and the tumor suppressor p53.
Graduate student Travis Witkowski, BS, in the Biomedical Sciences Graduate Program, studies tumor initiating cells (TIC), whose functional differences from other cancer cells in a tumor provide a mechanism of recurrence in HNSCC. He is developing both marker-dependent and functional assays to identify TIC and is investigating drugs that modulate TIC.
Senior Research Associate Jun-Ge Yu, MD, MS, provides scientific and technical support in histopathology and immunohistochemistry for the laboratory. Jun-Ge develops patient-derived tumor xenografts (PDX) in mice from human head and neck tumors or cells grown in culture, to evaluate intra-tumor heterogeneity and devise preclinical screens for the development of novel cancer therapeutics. He also helps other lab members establish and monitor animal experimental models.
Program Director Bhavna, Kumar, MS, provides scientific and technical oversight of the Rocco Laboratory and other laboratories in the Head and Neck Cancer Research Program at Ohio State while she is engaged in several research projects in these laboratories. In the Rocco Laboratory she is particularly helping to develop tumorsphere assays as a model of CSC.
Administrative Manager Gaila Konneker, MEd, provides budgetary and administrative support to the Rocco Laboratory and other laboratories in the Head and Neck Cancer Research Program of the Department of Otolaryngology-Head and Neck Surgery. She maintains fiscal accountability, ensuring that resources are efficiently used to reach program goals, and helps plan future initiatives. Gaila also serves as liaison with other departments, programs and offices at Ohio State and assists the department chair, division director and COO with faculty and staff recruitment, travel and hiring.
Former Lab Member:
Research Associate 1 Anita Janssen, BS, played a fundamental role in establishing the Rocco Laboratory at Ohio State after its move from Boston in 2015. She was responsible for day-to-day lab functions, overseeing staff training and safety, ordering supplies, and performing equipment maintenance and upkeep. She found, expanded, organized and documented the many cancer cell lines and other reagents that came from Boston, allowing the laboratory’s work to proceed efficiently. After two years in the Rocco Laboratory as the self-described “Lab Mom,” she took a position in the Clinical Trials Office at the OSUCCC – James.
Graduate student Jorge Toro-Zapata, BS, in the Biomedical Sciences Graduate Program, is working to determine the ways that carcinogenic stimuli normally lead to expression of the p16 tumor suppressor from the CDKN2A gene. This tumor suppression is almost always lost before HNSCC develop. He is investigating a protein complex including the C-terminal binding protein (CtBP), which helps determine whether p16 expression is kept off or turned on. Understanding the ways that p16 normally is engaged to prevent tumor development may provide ways to detect and treat disease at an early stage before dangerous heterogeneity can develop.